A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Exploratory, 28-Day Study to Examine the Effects of AR9281 on Blood Pressure and Glucose Tolerance in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Exploratory, 28-Day Study to Examine the Effects of AR9281 on Blood Pressure and Glucose Tolerance in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs AR 9281 (Primary)
  • Indications Glucose intolerance; Hypertension
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Arete Therapeutics
  • Most Recent Events

    • 21 Nov 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 21 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top